Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Lonza will support the development and manufacturing of CTIM-76, a CLDN6 x CD3 bispecific antibody clinical candidate. The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells expressing CLDN6.
Lead Product(s): CTIM-76
Therapeutic Area: Oncology Product Name: CTIM-76
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Context Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 09, 2023